Biomarkers will be one of the major drivers of biotech research, drug and diagnostics development in 21st century medicine. Dr. Jogarao Gobburu (Division of Pharmacometrics, FDA), Stephen Little (Qiagen), Mark Erwin (Prometheus Laboratories), Dr. Bryan Dechairo, (Medco Research Institute) and Dr. Christoph Huls (Merck Serono), explored the evolving business model for biomarkers and personalized medicine during a panel discussion at the 2011 BIO International Convention in Washington D.C. Mark Erwin summarized the common theme throughout the discussion: “Personalized medicine holds the promise for not only greatly improving healthcare for patients all over the world, but to generate cost savings and increase efficiencies in the healthcare system. All of us as healthcare stakeholders need to do what we can to incentivize this innovation.” Watch the video.
No comments:
Post a Comment